CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

The presentation will feature the design and objectives of the Phase 1 study, which marks the first clinical application of ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Two-Part Dose Escalation and Expansion Trial Will Evaluate Efficacy and Safety of BYON4228 Alone and in Combination with Pembrolizumab NIJMEGEN, The ...

Stage 4 lymphoma is a blood cancer that has spread outside of the lymph nodes to other parts of the body. Learn the symptoms, ...

Beloved Australian actor, Magda Szubanski, has revealed she's been diagnosed with a "very rare, very aggressive, very serious ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

At the AD/PD meeting held last month in Vienna, scientists implicated T lymphocytes—specifically, the cytotoxic, CD8-positive variety—in Alzheimer’s disease. While the modus operandi of these cells in ...

This poster presents a feeder-free protocol that enables scalable differentiation of iPSCs into CD8+ single-positive cytotoxic T cells, offering a robust platform for immunotherapy development.

CAR T cell immunotherapy, which uses a patient's own modified immune cells to find and destroy cancer cells, can produce ...